China SXT Pharmaceuticals Terminates Additional Purchase Right in Registered Direct Offering
China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) has officially entered into a termination agreement regarding its registered direct offering originally announced on October 8, 2026. The agreement specifically cancels the additional purchase right previously granted to purchasers under Section 2.4 of the securities purchase agreement. Under the original terms, purchasers held the option to buy up to an additional $12 million in Class A ordinary shares and/or pre-funded warrants within a 30-day window following the offering's closing. This termination removes any further entitlement for these purchasers to exercise that specific right, though all other provisions of the original securities purchase agreement remain intact.
Topics: Equity Financing Registered Direct Offering Termination Agreement